Loading...
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler, M Yang, J C-H Park, K Kim, J-H Bennouna, J Chen, Y-M Chouaid, C De Marinis, F Feng, J-F Grossi, F
Schuler, M
Yang, J C-H
Park, K
Kim, J-H
Bennouna, J
Chen, Y-M
Chouaid, C
De Marinis, F
Feng, J-F
Grossi, F
Citations
Altmetric:
Abstract
Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade with afatinib plus paclitaxel has superior outcomes versus switching to chemotherapy alone in patients acquiring resistance to erlotinib/gefitinib and afatinib monotherapy.
Description
Date
2016-03
Publisher
Collections
Files
Keywords
Type
Article
Citation
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. 2016, 27 (3):417-23 Ann. Oncol.